InnoCare Pharma (FRA:33C) EV-to-EBIT : -7.36 (As of May. 15, 2024)

View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, InnoCare Pharma's Enterprise Value is €321.27 Mil. InnoCare Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-43.67 Mil. Therefore, InnoCare Pharma's EV-to-EBIT for today is -7.36.

The historical rank and industry rank for InnoCare Pharma's EV-to-EBIT or its related term are showing as below:

FRA:33C' s EV-to-EBIT Range Over the Past 10 Years
Min: -216.63 Med: -29.55 Max: 1.57
Current: -12.45

During the past 7 years, the highest EV-to-EBIT of InnoCare Pharma was 1.57. The lowest was -216.63. And the median was -29.55.

FRA:33C's EV-to-EBIT is ranked worse than
100% of 427 companies
in the Biotechnology industry
Industry Median: 10.05 vs FRA:33C: -12.45

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. InnoCare Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was €461.22 Mil. InnoCare Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-43.67 Mil. InnoCare Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -9.47%.

InnoCare Pharma EV-to-EBIT Historical Data

The historical data trend for InnoCare Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma EV-to-EBIT Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-30.95

-790.43

-15.79

-7.00

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial												-15.79	-9.12	-3.56	-7.00	-

Competitive Comparison of InnoCare Pharma's EV-to-EBIT

For the Biotechnology subindustry, InnoCare Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InnoCare Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's EV-to-EBIT falls into.

InnoCare Pharma EV-to-EBIT Calculation

InnoCare Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	321.265	/	-43.672
	=	-7.36

InnoCare Pharma's current Enterprise Value is €321.27 Mil.
InnoCare Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-43.67 Mil.

InnoCare Pharma (FRA:33C) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

InnoCare Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-43.672	/	461.2208
	=	-9.47 %

InnoCare Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was €461.22 Mil.
InnoCare Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-43.67 Mil.

InnoCare Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (FRA:33C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

09969:Hong Kong 33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines